The therapeutic potential of targeting anti-Ribosomal-P antibody in treating SLE patients with depression

Expert Opinion on Biological Therapy

Volumn 7, Issue 9, 2007, Pages 1283-1285

  Blank, Miri ^a   Beinglass, Imbal ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti ribos.P; Autoantibodies; Autoimmunity; Depression; SLE

Indexed keywords

ABETIMUS; AUTOANTIBODY; IMMUNOGLOBULIN; PROTEIN ANTIBODY; RIBOSOME PROTEIN; RITUXIMAB;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL THERAPY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; IN VITRO STUDY; LIMBIC CORTEX; NERVE CELL; NONHUMAN; PROTEIN BINDING; PROTEIN TARGETING; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; DEPRESSIVE DISORDER; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; RIBOSOMAL PROTEINS;

MUS;

EID: 34748845384     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.9.1283     Document Type: Review

References (20)

1. ACR AD HOC COMMITTEE ON NEUROPSYCHIATRY LUPUS NOMENCLATURE: The American college of rheumatology nomenclature and case definitions for neuropsychiatry lupus syndromes. Arthritis Rheum. (1999) 42(4):599-608.
2. GREENWOOD DL, GITLITS VM, ALDERUCCIO F, SENTRY JW, TOH BH: Autoantibodies in neuropsychiatry lupus. Autoimmunity (2002) 35(2):7986.
3. ELKON KB, PARNASSA AP, FOSTER C: Lupus autoantibodies target ribosomal-P proteins. J Exp. Med. (1985) 162(2):459-471.
4. BONFA E, GOLOMBEK SJ, KAUFMAN LD et al.: Association between lupus psychosis and anti-ribosomal-P protein antibodies. N. Engl. J. Med. (1987) 317(5):265-271.
5. EBER T, CHAPMAN J, SHOENFELD Y: Anti-ribosomal-P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality? Lupus (2005) 14(8):571-575.
6. GABURO N, TIMOIARIA C, BEUNO C, COSSERMELLI W, CONFA E: In-vivo effects of antiribosomal-P-protein antibodies injections into lateral ventricle of the rat-brain. Arthritis Rheum. (1995) 38(S9):864 (Abstract).
7. KATZAV A, SOLODEEV I, BRODSKY O et al.: Induction of autoimmune depression in mice by anti-ribosomal-P antibodies via the limbic system. Arthritis Rheum. (2007) 56(3):938-948.
8. GAIPL US, SHERIFF A, FRANZ S et al.: Inefficient clearance of dying cells and autoreactivity. Curr. Top. Microbiol. Immunol. (2006) 305:161-176.
9. GAUBITZ M, HERRMANN M, SHAHIN M, SCHOTTE H, WILLEKE P, DOMSCHKE W: Cat scratch disease (bartonellosis) mimicking an SLE flare. Lupus (2001) 10(12):883-885.
10. ZHANG W, REICHLIN M: Production and characterization of human monoclonal anti-idiotype to anti-ribosomal-P antibodies. Clin. Immunol. (2005) 114(2):130-136.
11. KAVERI SV, DIETRICH G, HUREZ V, KAZACJLOME MD: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin. Exp. Immunol. (1991) 86(2): 192-198.
12. SHERER Y, SHOENFELD Y: Idiotypic network dysregulation: a common etiopathogenesis of diverse autoimmune diseases. Appl. Biochem. Biotechnol. (2000) 83(1-3):155-162.
13. SHOENFELD Y, RAUOVA L, GILBURD B et al.: Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int. Immunol. (2002) 14(11):1303-1311.
14. BLANK M, ANAFI L, ZANDMAN-GODDARD G et a.: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int. Immunol. (2007) 19(7):857-865.
15. PAN ZJ, ANDERSON CJ, STAFFORD HA: Anti-idiotypic antibodies prevent the serologic detection of antiribosomal-P autoantibodies in healthy adults. J. Clin. Invest. (1998) 102(1):215-222.
16. MILSTONE AM, MEYERS K, ELIA J: Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature. Clin. Rheumatol. (2005) 24(4):394-397.
17. LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50(8):2580-2589.
18. SFIKAKIS PP, SOULIOTlS VL, FRAGIADAKI HM, MOUTSOPOULOS KG, BOLETIS JN, THEOFILOPOULUS AN: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. (2007) 123(1):66-73.
19. TOKUNAGA M, SAITO K, KAWABATA D et al.: Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann. Rheum. Dis. (2007) 66(4):470-475.
20. ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 8(2):442-454.